Arbutus Biopharma Competitors, Revenue, Alternatives and Pricing

Claim your profile


Warminster, PA USA
Total Funding:$127M
Lead Investor(s):N/A

Estimated Revenue & Financials

  • Arbutus Biopharma's estimated annual revenue is currently $28.7M per year.(?)
  • Arbutus Biopharma's estimated revenue per employee is $155,000
  • Arbutus Biopharma's total funding is $127M.

Employee Data

  • Arbutus Biopharma has 185 Employees.(?)
  • Arbutus Biopharma currently has 1 job openings.

Arbutus Biopharma Corporation is a publicly-traded (NASDAQ: ABUS) biopharmaceutical company dedicated to discovering, developing and commercializing a cure for patients suffering from chronic hepatitis B infection, a disease of the liver caused by hepatitis B virus (HBV). We believe that Arbutus' comprehensive HBV pipeline of drugs and drug candidates optimally positions us to transform the HBV treatment landscape and to capitalize on the HBV global market opportunity. We are developing a portfolio of drug candidates with multiple mechanisms of action that we believe will result in a combination therapy to cure HBV.